- Home
- KPRX vs DWTX Comparison
KPRX vs DWTX Comparison
Compare KPRX & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- DWTX
- Stock Information
- Founded
- KPRX 1998
- DWTX 2012
- Country
- KPRX United States
- DWTX United States
- Employees
- KPRX N/A
- DWTX N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DWTX
- Sector
- KPRX Health Care
- DWTX
- Exchange
- KPRX Nasdaq
- DWTX NYSE
- Market Cap
- KPRX 9.1M
- DWTX 10.1M
- IPO Year
- KPRX N/A
- DWTX N/A
- Fundamental
- Price
- KPRX $3.08
- DWTX $4.89
- Analyst Decision
- KPRX Strong Buy
- DWTX Strong Buy
- Analyst Count
- KPRX 1
- DWTX 1
- Target Price
- KPRX $10.00
- DWTX $10.00
- AVG Volume (30 Days)
- KPRX 1.3M
- DWTX 107.9K
- Earning Date
- KPRX 05-09-2025
- DWTX 05-08-2025
- Dividend Yield
- KPRX N/A
- DWTX N/A
- EPS Growth
- KPRX N/A
- DWTX N/A
- EPS
- KPRX N/A
- DWTX N/A
- Revenue
- KPRX $20,000.00
- DWTX N/A
- Revenue This Year
- KPRX N/A
- DWTX N/A
- Revenue Next Year
- KPRX N/A
- DWTX N/A
- P/E Ratio
- KPRX N/A
- DWTX N/A
- Revenue Growth
- KPRX N/A
- DWTX N/A
- 52 Week Low
- KPRX $2.51
- DWTX $1.62
- 52 Week High
- KPRX $5.55
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- KPRX 48.79
- DWTX N/A
- Support Level
- KPRX $2.90
- DWTX N/A
- Resistance Level
- KPRX $4.18
- DWTX N/A
- Average True Range (ATR)
- KPRX 0.26
- DWTX 0.00
- MACD
- KPRX 0.00
- DWTX 0.00
- Stochastic Oscillator
- KPRX 19.12
- DWTX 0.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.